Mumbai, 20th March, 2026: DrStore Healthcare Services, a connected healthcare and medical device ecosystem company, through its smart medical devices and tech platform Tracky, has launched an integrated, real-time monitoring platform designed to track patient outcomes for GLP-1 therapies in India. The platform brings together multiple health data streams into a unified system, enabling clinicians and pharmaceutical companies to monitor therapy effectiveness, improve patient management, and generate real-world evidence.

The rapid rise of GLP-1 therapies for diabetes and weight management is reshaping the treatment landscape in India and globally. However, as adoption accelerates, a critical gap is becoming increasingly evident, the lack of continuous, structured data to monitor patient outcomes and understand therapy effectiveness in real-world settings.

Addressing this gap, Tracky is pioneering an integrated, real-time monitoring platform designed to bring together multiple health data streams into a unified, continuous view of patient health. The platform integrates glucose data from continuous glucose monitoring (CGM), Body composition tracking, Food logs & calorie tracking, activity levels, and wearable inputs, enabling longitudinal tracking and deeper insights into patient progress. Within the context of GLP-1 therapies, it supports real-time tracking of patient progress, enabling clinicians to make more informed decisions around dosage titration, identify and manage side effects early, and monitor adherence to therapy. By correlating these parameters with lifestyle and behavioral data, the platform also helps in understanding the sustainability of outcomes, supporting a more structured and data-driven approach to weight management during and after GLP therapy.

Today, GLP therapy delivery remains largely episodic, with limited visibility into how patients are responding between clinical visits. This absence of continuous data restricts clinicians’ ability to optimize treatment, while also limiting pharmaceutical companies in generating meaningful real-world evidence on therapy performance. By enabling correlation across these parameters, Tracky’s platform moves beyond isolated metrics to provide a more comprehensive and actionable understanding of metabolic health. This allows for more precise monitoring of how patients are responding to GLP therapies in real-world settings.

The platform also addresses a growing concern around GLP-1 treatments, the sustainability of outcomes after therapy discontinuation. While these therapies have shown strong clinical results, maintaining weight loss and metabolic improvements post-treatment remains a challenge. By combining continuous monitoring with lifestyle-linked insights, Tracky aims to support a more sustainable and data-driven approach to weight management, both during and beyond the therapy cycle.

For clinicians, the platform enables more informed, evidence-based decisions across dosage titration, side-effect monitoring, and co-morbidity management. For pharmaceutical companies, it creates a structured framework for patient monitoring programs, adherence tracking, and real-world evidence generation at scale.

“GLP therapies are transforming metabolic care, but their full impact depends on how well we can monitor and understand patient outcomes beyond the prescription,” said Neeraj Katare, Founder, Tracky. “We are building a continuous data layer that connects therapy with real-world patient insights enabling better decisions for clinicians and more meaningful evidence for pharmaceutical partners.”

Dr. Jothydev Kesavadev, MBBS, MD, FRCP, FACP, FACE(USA), Chairman, at Jothydev's Diabetes and Research Center, Trivandrum, India, said, “While GLP-1 therapies are driving strong clinical outcomes, there is still a gap when it comes to tracking patient progress in real-world settings. A platform that enables continuous monitoring and brings together multiple health parameters can help bridge this gap, offering better visibility into outcomes and enabling more proactive patient management.”

“One of the biggest challenges with GLP therapies today is the lack of continuous visibility into how patients are responding outside the clinic. A platform that enables real-time monitoring of parameters like glucose, weight, and activity can significantly improve how we titrate treatment, manage side effects, and make more informed clinical decisions”, said Dr. Banshi Saboo, Chairman, International Diabetes Federation, South East Asia.

Many large pharmaceutical companies have already adopted Tracky’s integrated platform into their GLP therapy programs to monitor adherence & patient outcome.